Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adolescent (≥12 years to \<18 years, and weighing ≥40 kg).~2. Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit.~3. Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit.~4. Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit~5. ≥10% body surface area (BSA) of AD involvement at the baseline visit.~6. History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.~Exclusion Criteria:~1. Participation in a prior lebrikizumab clinical study.~2. Treatment with the following prior to the baseline visit:~   1. An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer.~  2. Dupilumab within 8 weeks.~  3. B-cell-depleting biologics, including to rituximab, within 6 months.~  4. Other biologics within 5 half-lives (if known) or 16 weeks, whichever is longer.~3. Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study.~4. Uncontrolled chronic disease that might require bursts of oral corticosteroids.~5. Evidence of active acute or chronic hepatitis~6. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.~7. History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.~8. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lebrikizumab 250 mg (Type: EXPERIMENTAL): Participants received two subcutaneous (SC) injections of 250 milligram(mg) Lebrikizumab at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 up to (but not including) Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).